Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly And Co (NYSE:LLY), on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback